Amidst growing concerns of an opioid-abuse epidemic in the United States, it has been established that kratom (Mitragynine) is increasing in popularity amongst opioid users and has been reported as the new ‘legal high’.

Kratom is an unendorsed herb substance which has not yet been criminalized in the United States and is considered a powerful analgesic with opioid-like effects at high doses and acts as a stimulant at lower doses. Often used as a treatment for chronic pain or opiate withdrawal patients, it also comes in the form of a dietary supplement. As there are no Federal regulations monitoring the sale and distribution of Kratom the substance continues to be readily available and easily accessible via the internet, increasing its abuse by chronic pain patients on prescription opioids.

Kratom has been associated with psychosis, seizures, and has recently cited 100 deaths over a 17-month period by the Centers for Disease Control and Prevention (CDC). In previous reports, the Food and Drug Administration had warned against the use of Kratom to ease opioid withdrawal, as many pain physicians are not familiar about its addictive properties. Further the DEA plans to classify kratom as a Schedule 1 substance.

Are you testing for Kratom?

Randox Toxicology are the only suppliers for the detection of Kratom. Alongside our exclusive highly sensitive kratom ELISA test, this drug of abuse is available on our New Psychoactive Substances II panel, which utilises our universally available patented Biochip Array Technology.

Offering excellent cross-reactivity and unrivalled limits of detection over a range of routine and novel assays Biochip Array Technology is the world’s first multiplex screening technology. Designed to work across multiple matrices such as urine, blood, and oral fluid its intra and inter assay precision is typically <10% giving excellent correlation with confirmatory methods.

For more information regarding our Kratom tests get in touch with us by emailing info@randoxtoxicology.com